HeyJaredNephro Trial Files
Free bimonthly newsletter that summarizes the most significant, practice-changing nephrology randomized controlled trials, straight to your inbox.
- Indexed issues, last 90 days
- 2
- Latest publication
- Sep 3, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 9, 2026
Latest issues
Nephro Trial Files: Iptacopan in IgA Nephropathy, Low-Dose Rivaroxaban in Advanced CKD, and Finerenone in CKD due to Glomerular Disease (opens the original)
Read excerpt
Iptacopan in IgA Nephropathy — Final 24-Month DataBarratt J et al. NEJM (March 2026)Bottom Line: This phase 3 trial enrolled 477 adults with IgA nephropathy and an eGFR of at least 30 ml per minute per 1.73 m². Participants were randomly assigned to receive oral iptacopan (200 mg) or placebo twice daily for 9 months. The primary outcome was the annualized total eGFR slope over 24 months, showing -3.10 ml per minute per 1.73 m² per year for iptacopan versus -6.12 ml per minute per 1.73 m² per yea
Nephro Trial Files Throwback Thursday: Finerenone in CKD+T2DM, Renal-Replacement Therapy in AKI, and Hemodiafiltration (opens the original)
Read excerpt
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesBakris GL et al. NEJM (October 2020)Bottom Line: This double-blind, randomized trial (FIDELIO-DKD) enrolled 5,734 patients with chronic kidney disease and type 2 diabetes receiving maximally tolerated renin–angiotensin system blockade to compare <a href="https
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.